You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Funded Biomarker Testing

Find an overview of funded biomarker testing in Ontario. Information listed includes diagnostic, predictive and prognostic markers, as well as a summary of testing sites.

Disponible en anglais seulement. Vous pouvez demander un version française.

Funded Biomarker Testing

34 items

Assessment of gene amplification (e.g. MDM2, CDK4, BCOR)

Funded Biomarker Disease Site:
Biomarker:
Testing Method:FISH, Array, and/or Sequencing
Testing Site: Hamilton Health Sciences, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, The Ottawa Hospital

Immunohistochemical evaluation, where indicated, to assess line of differentiation for classification

Funded Biomarker Disease Site: Soft Tissue
Biomarker:
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, The Ottawa Hospital

Newly diagnosed cases of cervical carcinoma where HPV cannot be determined from histology/p16 staining.

Funded Biomarker Disease Site: Cervix
Biomarker: HPV
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, University Health Network

Newly diagnosed cases of penile carcinoma where HPV cannot be determined from histology/p16 staining.

Funded Biomarker Disease Site: Penile
Biomarker: HPV
Testing Method:In Situ Hybridization (ISH)
Testing Site: Hamilton Health Sciences, Health Sciences North, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, University Health Network

Reflex testing for the diagnosis of serous tumours (epithelial ovarian, fallopian tube, peritoneal cancers) when needed to establish histologic subtype.

Funded Biomarker Disease Site: Ovary
Biomarker: p53, WT1
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North Bay Regional Health Centre, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System

Reflex testing on all newly diagnosed breast cancers.

Funded Biomarker Disease Site: Breast
Biomarker: HER2, ER, PR
Testing Method:Immunohistochemistry (IHC)
Testing Site: Grand River Hospital, Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, Lakeridge Health, London Health Sciences Centre, Mount Sinai Hospital, North York General Hospital, Royal Victoria Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Thunder Bay Regional Health Sciences Centre, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System, Windsor Regional Hospital

Reflex testing on all newly diagnosed breast cancers.

Funded Biomarker Disease Site: Breast
Biomarker: HER2
Testing Method:In Situ Hybridization (ISH)
Testing Site: Grand River Hospital, Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, Lakeridge Health, London Health Sciences Centre, Mount Sinai Hospital, North York General Hospital, Royal Victoria Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Thunder Bay Regional Health Sciences Centre, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System, Windsor Regional Hospital

Reflex testing on all newly diagnosed ductal carcinoma in situ (DCIS).

Funded Biomarker Disease Site: Breast
Biomarker: ER
Testing Method:Immunohistochemistry (IHC)
Testing Site: Grand River Hospital, Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, Lakeridge Health, London Health Sciences Centre, Mount Sinai Hospital, North York General Hospital, Royal Victoria Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Thunder Bay Regional Health Sciences Centre, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System, Windsor Regional Hospital

Reflex testing on newly diagnosed cases advanced*/metastatic colorectal or small bowel carcinoma.

Funded Biomarker Disease Site: Colorectal, Small Bowel
Biomarker: BRAF, KRAS, NRAS, PIK3CA Optional for 21/22: PTEN
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System

Reflex testing on newly diagnosed cases of advanced*/metastatic melanoma.

Funded Biomarker Disease Site: Melanoma
Biomarker: BRAF, KIT, NRAS
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System

Reflex testing on newly diagnosed CD117 (cKIT) positive Gastrointestinal Stromal Tumours

Funded Biomarker Disease Site: Soft Tissue
Biomarker: BRAF, KIT, PDGFRA (Optional 23/24 - SDH, NTRK (fusion))
Testing Method:Sequencing
Testing Site: Hamilton Health Sciences, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, University Health Network

Reflex testing on newly diagnosed epithelial and low malignant potential ovarian tumours.

Funded Biomarker Disease Site: Ovary
Biomarker: MLH1, MSH2, MSH6, PMS2
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System

Pages